shanghai institute of materia medica
Powerful Lasers Shed Light On Vision
Using the most powerful laser in the world, scientists have solved the structure of the GPCR rhodopsin to unprecedented detail.
One Receptor, Two Disparate Binding Sites
The unusual dual binding sites of the GPCR P2Y1R could lead to new blood clotting drugs.
SIMM, Crown BioScience To Build Mouse Xenograft Model Center
Shanghai Institute of Materia Medica and Crown BioScience, Inc. have agreed to jointly build a mouse clinical trial center in China.
3SBio To Develop DJ5 For Progressive Renal Failure
3SBio Inc. has acquired patents for DJ5 to develop DJ5 as a treatment for progressive renal failure in patients with autosomal dominant polycystic kidney disease.
Servier To License Lucitanib To SIMM In China
Servier and the Shanghai Institute of Materia Medica will collaborate on the development of lucitanib, a targeted antitumor drug candidate with anti-angiogenic effects, in China.
